{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T19:15:53Z","timestamp":1786994153388,"version":"build-2736575974"},"reference-count":65,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100008349","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008349","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","metabolismjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Metabolism"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1016\/j.metabol.2021.154961","type":"journal-article","created":{"date-parts":[[2021,12,24]],"date-time":"2021-12-24T03:04:57Z","timestamp":1640315097000},"page":"154961","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":39,"special_numbering":"C","title":["The clustering of Cardiovascular, Renal, Adipo-Metabolic Eye and Liver disease with type 2 diabetes"],"prefix":"10.1016","volume":"128","author":[{"given":"M.C.","family":"Thomas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.metabol.2021.154961_bb0005","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.diabres.2013.11.002","article-title":"Global estimates of diabetes prevalence for 2013 and projections for 2035","volume":"103","author":"Guariguata","year":"2014","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.metabol.2021.154961_bb0010","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1186\/s12933-021-01344-0","article-title":"CAPTURE: a multinational, cross-sectional study of cardiovascular disease prevalence in adults with type 2 diabetes across 13 countries","volume":"20","author":"Mosenzon","year":"2021","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.metabol.2021.154961_bb0015","series-title":"Cardiovascular disease, diabetes and chronic kidney disease: Australian facts: prevalence and incidence 2014","author":"Welfare AIoHa","year":"2015"},{"key":"10.1016\/j.metabol.2021.154961_bb0020","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1056\/NEJMoa1608664","article-title":"Mortality and cardiovascular disease in type 1 and type 2 diabetes","volume":"376","author":"Rawshani","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.metabol.2021.154961_bb0025","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1016\/S0140-6736(10)60484-9","article-title":"Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies","volume":"375","author":"Emerging Risk Factors","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.metabol.2021.154961_bb0030","doi-asserted-by":"crossref","first-page":"e011295","DOI":"10.1161\/JAHA.118.011295","article-title":"Diabetes mellitus-related all-cause and cardiovascular mortality in a national cohort of adults","volume":"8","author":"Raghavan","year":"2019","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.metabol.2021.154961_bb0035","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1111\/jdi.12932","article-title":"Prevalence of diabetes and its effects on stroke outcomes: a meta-analysis and literature review","volume":"10","author":"Lau","year":"2019","journal-title":"J Diabetes Investig"},{"key":"10.1016\/j.metabol.2021.154961_bb0040","doi-asserted-by":"crossref","first-page":"434","DOI":"10.2337\/diacare.16.2.434","article-title":"Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial","volume":"16","author":"Stamler","year":"1993","journal-title":"Diabetes Care"},{"key":"10.1016\/j.metabol.2021.154961_bb0045","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1161\/CIRCULATIONAHA.114.012883","article-title":"Diabetes medications and heart failure: recognizing the risk","volume":"130","author":"Fonarow","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.metabol.2021.154961_bb0050","doi-asserted-by":"crossref","first-page":"85","DOI":"10.5694\/mja2.51101","article-title":"Hospital admissions for cardiovascular complications of people with or without diabetes, Victoria, 2004\u20132016","volume":"215","author":"K","year":"2021","journal-title":"Med J Aust"},{"key":"10.1016\/j.metabol.2021.154961_bb0055","doi-asserted-by":"crossref","first-page":"2614","DOI":"10.2337\/dc20-0654","article-title":"Incidence of hospitalization for heart failure relative to major atherosclerotic events in type 2 diabetes: a meta-analysis of cardiovascular outcomes trials","volume":"43","author":"Sacre","year":"2020","journal-title":"Diabetes Care"},{"key":"10.1016\/j.metabol.2021.154961_bb0060","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S2213-8587(14)70219-0","article-title":"Type 2 diabetes and incidence of cardiovascular diseases: a cohort study in 1.9 million people","volume":"3","author":"Shah","year":"2015","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.metabol.2021.154961_bb0065","series-title":"The economic costs of atrial fibrillation in Australia","year":"2010"},{"key":"10.1016\/j.metabol.2021.154961_bb0070","first-page":"364","article-title":"Atrial fibrillation in patients with diabetes: molecular mechanisms and therapeutic perspectives","volume":"5","author":"De Sensi","year":"2015","journal-title":"Cardiovasc Diagn Ther"},{"key":"10.1016\/j.metabol.2021.154961_bb0075","series-title":"Australian diabetes-related foot disease strategy 20182022: the first step towards ending avoidable amputations within a generation","author":"Van Netten","year":"2017"},{"key":"10.1016\/j.metabol.2021.154961_bb0080","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.1056\/NEJMra1615439","article-title":"Diabetic foot ulcers and their recurrence","volume":"376","author":"Armstrong","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.metabol.2021.154961_bb0085","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta19570","article-title":"A systematic review and individual patient data meta-analysis of prognostic factors for foot ulceration in people with diabetes: the international research collaboration for the prediction of diabetic foot ulcerations (PODUS)","volume":"19","author":"Crawford","year":"2015","journal-title":"Health Technol Assess"},{"key":"10.1016\/j.metabol.2021.154961_bb0090","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.1161\/ATVBAHA.120.314595","article-title":"Epidemiology and risk of amputation in patients with diabetes mellitus and peripheral artery disease","volume":"40","author":"Barnes","year":"2020","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.metabol.2021.154961_bb0095","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1186\/s12933-018-0728-6","article-title":"Prevalence of cardiovascular disease in type 2 diabetes: a systematic literature review of scientific evidence from across the world in 2007\u20132017","volume":"17","author":"Einarson","year":"2018","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.metabol.2021.154961_bb0100","series-title":"IDF diabetes atlas","author":"Foundation ID","year":"2016"},{"key":"10.1016\/j.metabol.2021.154961_bb0105","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.2337\/dc16-0303","article-title":"Cardiovascular mortality in patients with type 2 diabetes and recent acute coronary syndromes from the EXAMINE trial","volume":"39","author":"White","year":"2016","journal-title":"Diabetes Care"},{"key":"10.1016\/j.metabol.2021.154961_bb0110","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1161\/CIRCULATIONAHA.114.014796","article-title":"Impact of diabetes mellitus on hospitalization for heart failure, cardiovascular events, and death: outcomes at 4 years from the Reduction of Atherothrombosis for Continued Health (REACH) Registry","volume":"132","author":"Cavender","year":"2015","journal-title":"Circulation"},{"key":"10.1016\/j.metabol.2021.154961_bb0115","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1161\/CIRCULATIONAHA.120.051824","article-title":"Effect of empagliflozin on cardiovascular and renal outcomes in patients with heart failure by baseline diabetes status: results from the EMPEROR-reduced trial","volume":"143","author":"Anker","year":"2021","journal-title":"Circulation"},{"key":"10.1016\/j.metabol.2021.154961_bb0120","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1136\/heartjnl-2015-307627","article-title":"Improving 30-day case fatality after incident myocardial infarction in people with diabetes between 1998 and 2010","volume":"101","author":"Nedkoff","year":"2015","journal-title":"Heart"},{"key":"10.1016\/j.metabol.2021.154961_bb0125","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.metabol.2021.154961_bb0130","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.numecd.2018.02.011","article-title":"Diabetes mellitus and the risk of sudden cardiac death: a systematic review and meta-analysis of prospective studies","volume":"28","author":"Aune","year":"2018","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"10.1016\/j.metabol.2021.154961_bb0135","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.kint.2020.06.019","article-title":"KDIGO 2020 clinical practice guideline for diabetes management in chronic kidney disease","volume":"98","author":"Kidney Disease: Improving Global Outcomes Diabetes Work G","year":"2020","journal-title":"Kidney Int"},{"key":"10.1016\/j.metabol.2021.154961_bb0140","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.1038\/sj.ki.5000377","article-title":"Prevalence and risk factors for microalbuminuria in a referred cohort of type II diabetic patients: a global perspective","volume":"69","author":"Parving","year":"2006","journal-title":"Kidney Int"},{"key":"10.1016\/j.metabol.2021.154961_bb0145","doi-asserted-by":"crossref","first-page":"1832","DOI":"10.2337\/db05-1620","article-title":"Risk factors for renal dysfunction in type 2 diabetes: U.K. Prospective Diabetes Study 74","volume":"55","author":"Retnakaran","year":"2006","journal-title":"Diabetes"},{"key":"10.1016\/j.metabol.2021.154961_bb0150","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1093\/ndt\/gfq535","article-title":"Risk factors for the development of albuminuria and renal impairment in type 2 diabetes\u2014the Swedish National Diabetes Register (NDR)","volume":"26","author":"Afghahi","year":"2011","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.metabol.2021.154961_bb0155","doi-asserted-by":"crossref","first-page":"2353","DOI":"10.2337\/diacare.26.8.2353","article-title":"Low incidence of end-stage renal disease and chronic renal failure in type 2 diabetes: a 10-year prospective study","volume":"26","author":"Bruno","year":"2003","journal-title":"Diabetes Care"},{"key":"10.1016\/j.metabol.2021.154961_bb0160","doi-asserted-by":"crossref","first-page":"2532","DOI":"10.1001\/jama.2011.861","article-title":"Temporal trends in the prevalence of diabetic kidney disease in the United States","volume":"305","author":"de Boer","year":"2011","journal-title":"JAMA"},{"key":"10.1016\/j.metabol.2021.154961_bb0165","doi-asserted-by":"crossref","DOI":"10.1186\/1478-7954-8-29","article-title":"Projection of the year 2050 burden of diabetes in the US adult population: dynamic modeling of incidence, mortality, and prediabetes prevalence","volume":"8","author":"Boyle","year":"2010","journal-title":"Popul Health Metr"},{"key":"10.1016\/j.metabol.2021.154961_bb0170","doi-asserted-by":"crossref","first-page":"15018","DOI":"10.1038\/nrdp.2015.18","article-title":"Diabetic kidney disease","volume":"1","author":"Thomas","year":"2015","journal-title":"Nat Rev Dis Prim"},{"key":"10.1016\/j.metabol.2021.154961_bb0175","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1093\/qjmed\/95.4.241","article-title":"Complications and cardiovascular risk factors in South Asians and Europeans with early-onset type 2 diabetes","volume":"95","author":"Chowdhury","year":"2002","journal-title":"QJM"},{"key":"10.1016\/j.metabol.2021.154961_bb0180","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1111\/j.1464-5491.1992.tb01860.x","article-title":"Increased incidence of end-stage renal failure secondary to diabetes mellitus in Asian ethnic groups in the United Kingdom","volume":"9","author":"Burden","year":"1992","journal-title":"Diabet Med"},{"key":"10.1016\/j.metabol.2021.154961_bb0185","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.2337\/dc06-0003","article-title":"South-Asian type 2 diabetic patients have higher incidence and faster progression of renal disease compared with Dutch-European diabetic patients","volume":"29","author":"Chandie Shaw","year":"2006","journal-title":"Diabetes Care"},{"key":"10.1016\/j.metabol.2021.154961_bb0190","doi-asserted-by":"crossref","first-page":"385","DOI":"10.7326\/M20-5938","article-title":"Diabetes management in chronic kidney disease: synopsis of the 2020 KDIGO clinical practice guideline","volume":"174","author":"Navaneethan","year":"2021","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.metabol.2021.154961_bb0195","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1038\/s41433-017-0003-1","article-title":"Cataract in patients with diabetes mellitus-incidence rates in the UK and risk factors","volume":"32","author":"Becker","year":"2018","journal-title":"Eye (Lond)"},{"key":"10.1016\/j.metabol.2021.154961_bb0200","doi-asserted-by":"crossref","first-page":"556","DOI":"10.2337\/dc11-1909","article-title":"Global prevalence and major risk factors of diabetic retinopathy","volume":"35","author":"Yau","year":"2012","journal-title":"Diabetes Care"},{"key":"10.1016\/j.metabol.2021.154961_bb0205","doi-asserted-by":"crossref","DOI":"10.1016\/j.ophtha.2021.04.027","article-title":"Global prevalence of diabetic retinopathy and projection of burden through 2045: systematic review and meta-analysis","author":"Teo","year":"2021","journal-title":"Ophthalmology"},{"key":"10.1016\/j.metabol.2021.154961_bb0210","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/j.jhep.2019.06.021","article-title":"The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: a systematic review and meta-analysis","volume":"71","author":"Younossi","year":"2019","journal-title":"J Hepatol"},{"key":"10.1016\/j.metabol.2021.154961_bb0215","doi-asserted-by":"crossref","first-page":"23","DOI":"10.2337\/db11-0555","article-title":"Nutrient sensing, autophagy, and diabetic nephropathy","volume":"61","author":"Kume","year":"2012","journal-title":"Diabetes"},{"key":"10.1016\/j.metabol.2021.154961_bb0220","doi-asserted-by":"crossref","DOI":"10.3390\/ijerph18158106","article-title":"The association of diabetic retinopathy and cardiovascular disease: a 13-year nationwide population-based cohort study","volume":"18","author":"Hsu","year":"2021","journal-title":"Int J Environ Res Public Health"},{"key":"10.1016\/j.metabol.2021.154961_bb0225","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1001\/jamaophthalmol.2017.0988","article-title":"Association of diabetic macular edema and proliferative diabetic retinopathy with cardiovascular disease: a systematic review and meta-analysis","volume":"135","author":"Xie","year":"2017","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.metabol.2021.154961_bb0230","doi-asserted-by":"crossref","DOI":"10.1016\/j.cgh.2021.02.027","article-title":"MAFLD and cardiovascular events: what does the evidence show?","author":"George","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.metabol.2021.154961_bb0235","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1007\/BF00285287","article-title":"Albuminuria reflects widespread vascular damage. The Steno hypothesis","volume":"32","author":"Deckert","year":"1989","journal-title":"Diabetologia"},{"key":"10.1016\/j.metabol.2021.154961_bb0240","doi-asserted-by":"crossref","first-page":"62","DOI":"10.2337\/dc17-2683","article-title":"Trajectory of excess medical expenditures 10 years before and after diabetes diagnosis among U.S. adults aged 25\u201364 years, 2001\u20132013","volume":"42","author":"Shrestha","year":"2019","journal-title":"Diabetes Care"},{"key":"10.1016\/j.metabol.2021.154961_bb0245","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.2337\/diacare.25.7.1129","article-title":"Elevated risk of cardiovascular disease prior to clinical diagnosis of type 2 diabetes","volume":"25","author":"Hu","year":"2002","journal-title":"Diabetes Care"},{"key":"10.1016\/j.metabol.2021.154961_bb0250","doi-asserted-by":"crossref","first-page":"140","DOI":"10.5694\/j.1326-5377.2006.tb00499.x","article-title":"The burden of chronic kidney disease in Australian patients with type 2 diabetes (the NEFRON study)","volume":"185","author":"Thomas","year":"2006","journal-title":"Med J Aust"},{"key":"10.1016\/j.metabol.2021.154961_bb0255","doi-asserted-by":"crossref","first-page":"190","DOI":"10.3892\/etm.2020.9320","article-title":"Prediction of NAFLD occurrence in prediabetes patients","volume":"20","author":"Vesa","year":"2020","journal-title":"Exp Ther Med"},{"key":"10.1016\/j.metabol.2021.154961_bb0260","doi-asserted-by":"crossref","DOI":"10.3390\/jcm9103289","article-title":"Chronic microvascular complications in prediabetic states-an overview","volume":"9","author":"Baranowska-Jurkun","year":"2020","journal-title":"J Clin Med"},{"key":"10.1016\/j.metabol.2021.154961_bb0265","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1161\/CIRCULATIONAHA.106.685628","article-title":"Risk of cardiovascular and all-cause mortality in individuals with diabetes mellitus, impaired fasting glucose, and impaired glucose tolerance: the Australian Diabetes, Obesity, and Lifestyle Study (AusDiab)","volume":"116","author":"Barr","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.metabol.2021.154961_bb0270","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1016\/j.dsx.2018.12.006","article-title":"Metabolic syndrome and its components are related to a higher risk for albuminuria and proteinuria: evidence from a meta-analysis on 10,603,067 subjects from 57 studies","volume":"13","author":"Rashidbeygi","year":"2019","journal-title":"Diabetes Metab Syndr"},{"key":"10.1016\/j.metabol.2021.154961_bb0275","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.1001\/jama.1990.03440210043030","article-title":"Cardiovascular risk factors in confirmed prediabetic individuals. Does the clock for coronary heart disease start ticking before the onset of clinical diabetes?","volume":"263","author":"Haffner","year":"1990","journal-title":"JAMA"},{"key":"10.1016\/j.metabol.2021.154961_bb0280","article-title":"Metabolic associated fatty liver disease is the risk factor for chronic kidney disease","author":"Hashimoto","year":"2021","journal-title":"J Diabetes Investig"},{"key":"10.1016\/j.metabol.2021.154961_bb0285","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1016\/j.jacc.2011.02.038","article-title":"Adiposopathy is \u201csick fat\u201d a cardiovascular disease?","volume":"57","author":"Bays","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.metabol.2021.154961_bb0290","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1517\/14796678.1.1.39","article-title":"Adiposopathy: sick fat causes high blood sugar, high blood pressure and dyslipidemia","volume":"1","author":"Bays","year":"2005","journal-title":"Future Cardiol"},{"key":"10.1016\/j.metabol.2021.154961_bb0295","doi-asserted-by":"crossref","first-page":"2080","DOI":"10.2337\/dc16-0619","article-title":"Type 2 diabetes: the pathologic basis of reversible beta-cell dysfunction","volume":"39","author":"White","year":"2016","journal-title":"Diabetes Care"},{"key":"10.1016\/j.metabol.2021.154961_bb0300","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1038\/s41575-021-00448-y","article-title":"The complex link between NAFLD and type 2 diabetes mellitus - mechanisms and treatments","volume":"18","author":"Targher","year":"2021","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.metabol.2021.154961_bb0305","doi-asserted-by":"crossref","first-page":"e840","DOI":"10.1161\/CIR.0000000000000664","article-title":"Cardiorenal syndrome: classification, pathophysiology, diagnosis, and treatment strategies: a scientific statement from the American Heart Association","volume":"139","author":"Rangaswami","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.metabol.2021.154961_bb0310","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1111\/j.1464-5491.1989.tb01266.x","article-title":"Non-insulin-dependent (type 2) diabetes mellitus: does it really exist?","volume":"6","author":"Zimmet","year":"1989","journal-title":"Diabet Med"},{"key":"10.1016\/j.metabol.2021.154961_bb0315","doi-asserted-by":"crossref","first-page":"2388","DOI":"10.1056\/NEJMsa053935","article-title":"Explaining the decrease in U.S. deaths from coronary disease, 1980\u20132000","volume":"356","author":"Ford","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.metabol.2021.154961_bb0320","doi-asserted-by":"crossref","DOI":"10.2337\/dc20-3023","article-title":"Cardiovascular outcomes in patients with type 2 diabetes and obesity: comparison of gastric bypass, sleeve gastrectomy, and usual care","author":"Aminian","year":"2021","journal-title":"Diabetes Care"},{"key":"10.1016\/j.metabol.2021.154961_bb0325","doi-asserted-by":"crossref","first-page":"116","DOI":"10.2337\/dc20-0571","article-title":"The impact of bariatric surgery on incident microvascular complications in patients with type 2 diabetes: a matched controlled population-based retrospective cohort study","volume":"44","author":"Singh","year":"2021","journal-title":"Diabetes Care"}],"container-title":["Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0026049521002614?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0026049521002614?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T04:28:20Z","timestamp":1758428900000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0026049521002614"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":65,"alternative-id":["S0026049521002614"],"URL":"https:\/\/doi.org\/10.1016\/j.metabol.2021.154961","relation":{},"ISSN":["0026-0495"],"issn-type":[{"value":"0026-0495","type":"print"}],"subject":[],"published":{"date-parts":[[2022,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The clustering of Cardiovascular, Renal, Adipo-Metabolic Eye and Liver disease with type 2 diabetes","name":"articletitle","label":"Article Title"},{"value":"Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.metabol.2021.154961","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"154961"}}